B
Bull
Bull · 25%TXG
$7.67
Scenario price
$61.540
-3.139 (-5.10%)At close
Loading chart…
- High
- 65.000
- Open
- 63.880
- VWAP
- 62.45
- Vol
- 2.36M
- Mkt Cap
- 2.38B
- Low
- 60.820
- Amount
- 147.47M
- EV/EBITDA, TTM
- -8.95
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Valuation Metrics
The current forward P/E ratio for 10X Genomics Inc (TXG) is -9.54, compared to its 5-year average forward P/E of -60.45.
Alphio AI Price Scenarios for TXG
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding TXG
Events Timeline
News
7.008-28NewsfilterJury Rules Parse Willfully Infringed Scale Biosciences' Patents
7.008-28PRnewswireJury Finds Parse Willfully Infringed Scale Biosciences' Patents
8.508-27stocktwitsARK Optimistic About Personalized Cancer Vaccine Future
9.508-15Yahoo Finance10x Genomics Q2 Earnings Call Insights
2.008-14NASDAQ.COM10x Genomics (TXG) Q2 2026 Earnings Call Transcript
TXG FAQ — answered by Alphio AI
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.